Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Dr. Schwartz on Future Research Efforts in Sarcoma

October 15th 2020

Gary K. Schwartz, MD, discusses future research efforts in the field of sarcoma.

Dr. Maki on the Potential Utility of Immunotherapy in Sarcoma

October 14th 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the potential utility of immunotherapy in sarcoma.

Dr. Tseng on the Significance of the TARPSWG Analysis in Retroperitoneal Sarcoma

October 9th 2020

William W. Tseng, MD, discusses the significance of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

Dr. D’Amato on the Diminishing Role of Chemotherapy in Sarcoma

October 9th 2020

Gina Z. D'Amato, MD, discusses the diminishing role of chemotherapy in sarcoma.

Lancet Oncology Data Reinforce Regulatory Approvals of Tazemetostat in Sarcoma, Follicular Lymphoma

October 9th 2020

Tazemetostat demonstrated durable responses and sustained safety in patients with epithelioid sarcoma and relapsed/refractory follicular lymphoma.

Dr. Maki on the Evolving Treatment Landscape in Soft Tissue Sarcoma

October 8th 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the evolving treatment landscape of soft tissue sarcoma.

Dr. Pautier on Challenges With Drug Development in Leiomyosarcoma

October 6th 2020

Patricia Pautier, MD, discusses limitations in leiomyosarcoma.

Dr. Tseng on the Rationale for the TARPSWG Analysis in Retroperitoneal Sarcoma

October 5th 2020

William W. Tseng, MD, discusses the rationale for the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

High-Grade Surface Osteosarcoma Exhibits Poor Oncologic Outcomes

October 5th 2020

The survival outcomes of patients with high-grade surface osteosarcoma is poor, despite the use of contemporary treatment with surgery and chemotherapy.

Dr. Abraham on the Surgical Management of TGCT

October 2nd 2020

John A. Abraham, MD, FACS, discusses the surgical management of patients with tenosynovial giant cell tumor.

Dr. Zalcberg on the Management of Patients With GIST

October 1st 2020

John Zalcberg, PhD, OAM, discusses the management of patients with gastrointestinal stromal tumor.

Regional Lymph Node Macroscopic Metastases in Sarcoma Linked With Poor OS Outcomes

September 30th 2020

The presence of macroscopic metastases in regional lymph nodes is found to be related to poor survival outcomes in patients with sarcoma.

Avapritinib Approved in Europe for PDGFRA D842V–Mutant GIST

September 28th 2020

The European Commission has granted a conditional marketing authorization to avapritinib for single agent use in adult patients with unresectable or metastatic gastrointestinal stromal tumors that harbor a PDGFRA D842V mutation.

Even in COVID-19 World, Children’s Oncology Group Tackles Unmet Needs in Sarcomas

September 28th 2020

R. Lor Randall, MD, highlights the innovative efforts by the COG, ongoing studies in sarcomas, and how the organization is adapting during a world with COVID-19.

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21st 2020

The feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demonstrated in the phase 1b TRAMUNE trial.

Pembrolizumab Prolongs PFS in Rare Sarcoma Subtypes

September 21st 2020

Pembrolizumab monotherapy prolonged progression-free survival in selected rare sarcoma subtypes, supporting the immune checkpoint inhibitor’s ability to improve outcomes across histotypes.

Regorafenib Showed Modest Activity in Ewing Sarcoma

September 20th 2020

Regorafenib extended progression-free survival at 24 weeks compared with placebo for patients with Ewing sarcoma in the phase 2 REGOBONE study. However, the oral multi-kinase inhibitor failed to meet the study’s primary endpoint of non-progression at 8 weeks.

Dr. Pautier on Remaining Challenges in Advanced Soft Tissue Sarcoma

September 11th 2020

Patricia Pautier, MD, discusses remaining challenges in treating patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.

Doxorubicin and Trabectedin Combo Impresses in Soft Tissue Sarcoma

September 8th 2020

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial, the importance of histologic stratification, and ongoing challenges in soft tissue sarcoma.

Dr. Pautier on the Rationale for the LMS-02 Trial in Soft Tissue Sarcoma

September 8th 2020

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial in uterine and soft tissue leiomyosarcoma.